Navigation Links
Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
Date:9/17/2009

SAN DIEGO, Sept. 17, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will hold a conference call and webcast presentation on Friday, September 18, 2009, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time) to discuss top-line results from BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), the second of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management.

The conference call may be accessed by dialing 888.312.3047 for domestic callers and 719.325.2234 for international callers. Please specify to the operator that you would like to join the "Lorcaserin BLOSSOM Trial Results" conference call. The conference call and slide presentation will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena has a broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, which includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
(Date:1/15/2014)... Ill. , Jan. 15, 2014 The Cadence ... Medical Fitness Center by the Medical Fitness Association, a ... to achieve their full potential. The Cadence Fitness & ... the western suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... ATLANTA, Nov. 28, 2011   CardioMEMS, Inc ., an ... commercializing a proprietary wireless sensing and communication technology for ... CEO, Jay Yadav, M.D. , has been recognized ... Endeavor Awards in the Technology Entrepreneur category. The awards ...
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
Cached Medicine Technology:TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 2TechAmerica and the Technology Association of Georgia Name Dr. Jay Yadav, CardioMEMS Founder & CEO as a Spirit of Endeavor Award Finalist 3PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2
(Date:4/15/2014)... mystery and in the process have found a potentially less ... million people a year. The researchers say they now understand the ... in use for more than 50 years even though it ... the microbes it attacks. , A report of the ...
(Date:4/14/2014)... children orphaned by HIV/AIDS in South Africa may provide insight ... issues in other areas of the world, which may have ... to successful interventions. , A report on the global ... to the HIV/AIDS pandemic, which has left 12 million children ...
(Date:4/14/2014)... shows that moderate to severe obstructive sleep apnea is independently associated ... of the 20-year follow-up study show that people with moderate to ... (hazard ratio = 4.2), nearly four times more likely to have ... from cancer (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... youth offenders, the answer to one open-ended question predicted the ... do you think you,ll live?", According to the study, having ... Dr. Alex Piquero said the study found those who don,t ... very high rates and commit more serious offenses, while those ...
(Date:4/14/2014)... fathers hard -- with symptoms increasing dramatically during some of ... Northwestern Medicine study has found. , Depressive symptoms increased on ... fatherhood for these young men, who were around 25 years ... same home as their children. The results of the study ...
Breaking Medicine News(10 mins):Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2
... Jan. 11 (HealthDay News) -- There is little evidence ... relieve the symptoms of osteoarthritis, according to a review ... that involves damage to cartilage and other structures in ... hips. It differs from rheumatoid arthritis, which is an ...
... of researchers at the California Institute of Technology (Caltech) ... The reaction they have come up with should enable ... of organic compounds called nitrogen-containing heterocycles, thus opening up ... natural products ranging from chemotherapeutic compounds to bioactive plant ...
... Denise Mann HealthDay Reporter , WEDNESDAY, Jan. ... their heart race when they are having an irregular ... double their risk of stroke, a new study finds. ... not have a history of atrial fibrillation, more than ...
... During 2010-2011, University of Louisville Health Sciences Center faculty ... $5.7 million in the four regions of Kentucky served ... faculty from UofL provided donated services valued at $5,606,599 ... living and travel expenses in the four regions. These ...
... -- A genetic mutation that causes a rare immune ... been identified by scientists. Symptoms of the disorder ... (cold urticaria), according to the report published online in ... Journal of Medicine . The U.S. National Institutes ...
... HealthDay Reporter , WEDNESDAY, Jan. 11 (HealthDay News) -- ... type 1 diabetes appears to help re-educate rogue immune system ... insulin again. The treatment, which combines a patient,s ... blood, even worked in people with long-standing diabetes who were ...
Cached Medicine News:Health News:Herbal Medicines for Arthritis Not Backed by Evidence 2Health News:Herbal Medicines for Arthritis Not Backed by Evidence 3Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 2Health News:Caltech chemists devise chemical reaction that holds promise for new drug development 3Health News:Even When Silent, Irregular Heartbeat Linked to Stroke Risk 2Health News:UofL centers have economic impact in excess of $5.7 million 2Health News:UofL centers have economic impact in excess of $5.7 million 3Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 2Health News:Novel Stem Cell Treatment May Hold Promise for Type 1 Diabetes 3
Inquire...
Sterilization: sterilized Yes...
Transparent film for easy visual monitoring of samples...
Microporous tape sheets for covering 96-well plates, square-well or flat-bottom blocks.;...
Medicine Products: